AU Patent

AU2009298139B2 — Compositions and methods for the treatment of bowel diseases with granulated mesalamine

Assigned to Dr Falk Pharma GmbH · Expires 2015-02-19 · 11y expired

What this patent protects

Disclosed are methods for treating gastrointestinal disorders, e.g., Crohn's disease, ulcerative colitis, and diverticular disease, with a granulated mesalamine formulation. Some formulations use granulated mesalamine in capsule form. Also included are methods to extend remission…

USPTO Abstract

Disclosed are methods for treating gastrointestinal disorders, e.g., Crohn's disease, ulcerative colitis, and diverticular disease, with a granulated mesalamine formulation. Some formulations use granulated mesalamine in capsule form. Also included are methods to extend remission of ulcerative colitis by administration of a once -daily dosage of granulated mesalamine.

Drugs covered by this patent

Patent Metadata

Patent number
AU2009298139B2
Jurisdiction
AU
Classification
Expires
2015-02-19
Drug substance claim
No
Drug product claim
No
Assignee
Dr Falk Pharma GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.